Atopic Dermatitis Drugs Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast 2024-2028

Atopic Dermatitis Drugs Market Size 2024-2028

The global atopic dermatitis drugs market size is estimated to grow by USD 6.20 billion at a CAGR of 10.87% between 2023 and 2028. The market's expansion hinges on several pivotal factors, notably the widespread occurrence of atopic dermatitis, escalating healthcare expenditure, and a robust R&D pipeline for dermatology. Atopic dermatitis, a prevalent skin condition, fuels the demand for effective treatments and management solutions, driving market growth. Concurrently, the escalating healthcare expenditure underscores the prioritization of dermatological health, fostering investment in advanced therapies and medical technologies. Moreover, a robust R&D pipeline ensures a continuous influx of innovative products and treatment modalities, further propelling market expansion. As the healthcare landscape evolves and scientific advancements continue, the atopic dermatitis market is poised for sustained growth, with a focus on improving patient outcomes and enhancing quality of life.

What will be the Size of the Atopic Dermatitis Drugs Market During the Forecast Period?

To learn more about this atopic dermatitis drugs market report, Download Report Sample

Atopic Dermatitis Drugs Market Segmentation

In the atopic dermatitis drugs market, innovative treatments like Ruxolitinib Cream and Crisaborole ointment signify a shift towards targeted therapies. The prevalence of this chronic inflammatory skin condition drives the demand for novel treatments, emphasizing patient-centric care models. With the rise of telemedicine adoption, healthcare access disparities are being addressed, particularly in regions where hospital pharmacies play a crucial role in dispensing medications, including dermatological drugs. Regulatory complexities notwithstanding, topical corticosteroids remain a mainstay in treatment, addressing symptoms like cracked and dry skin and hand eczema. Amidst Westernized lifestyles, oil-stripping soaps pose challenges, necessitating the development of novel products to combat the condition, especially among pediatric patients.

The market share growth by the oral segment will be significant during the forecast period. Factors such as the rising number of approvals of various oral drugs and over-the-counter drugs for atopic dermatitis and their benefits, such as ease of use, are expected to drive the segment growth, which in turn, is anticipated to propel the growth of the market in focus during the forecast period.

Get a glance at the market contribution of various segments. Download PDF Sample

The oral segment was valued at USD 2.46 billion in 2018. Easy-to-use benefits of drugs that are taken via the oral route and the growing popularity of prescription-based drugs and acne drugs, such as oral capsules, are driving the growth of the oral segment during the forecast period. For instance, in January 2022, AbbVie and Pfizer received approval for Upadacitinib and Abrocitinib from the US FDA for the treatment of refractory moderate to severe atopic dermatitis. Such developments are likely to propel the growth of the oral segment during the forecast period.

Regional Analysis

For more insights about the market share of various regions, Download PDF Sample now!

North America is estimated to contribute 37% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers will shape the market during the forecast period. Among all regions, North America accounted for the largest share of the global atopic dermatitis drug market in 2022. This is due to factors such as the high level of awareness of health care, and the presence of an established medical infrastructure in the region. In addition, the market is expected to show promising growth over the forecast period owing to favorable reimbursement policies, a rising number of drug approvals in the US, and rising healthcare costs. For instance, in the US, national healthcare spending grew by 2.7% in 2021 over 2020 and reached USD 4.3 trillion or USD 12,914 per person. Thus, the growing expenditure associated with healthcare is likely to increase the demand for atopic dermatitis drugs among patients in the region. 

Buy Full Report Now

Key Atopic Dermatitis Drugs Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

AbbVie Inc., Arcutis Biotherapeutics Inc., Asana BioSciences LLC, Astellas Pharma Inc., Bausch Health Companies Inc., Bayer AG, BiomX Inc., Bristol Myers Squibb Co., Dermavant Sciences Inc., Eli Lilly and Co., Evelo Biosciences Inc., Galderma SA, Incyte Corp., LEO Pharma AS, Maruho Co. Ltd., Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Sanofi SA, and Viatris Inc.

AbbVie Inc.: The company offers atopic dermatitis drugs such as RINVOQ. Also, they conduct research and development, manufacturing, commercialization, and sale of innovative medicines, medical devices, and therapies to allocate resources and assess business performance on a global basis to achieve established long-term strategic goals.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Atopic Dermatitis Drugs Market Dynamics and Customer Landscape

The market is driven by the increasing prevalence of chronic inflammatory skin conditions like atopic dermatitis. Novel treatments such as Ruxolitinib Cream and Crisaborole ointment offer targeted therapies, enhancing patient-centric care models. Telemedicine adoption facilitates healthcare access, especially for pediatric patients. However, regulatory complexities pose challenges to market growth. Westernized lifestyles contribute to the rise in disease prevalence, necessitating innovative solutions. Topical corticosteroids remain a cornerstone in treatment, despite concerns about long-term use. Addressing healthcare access disparities and promoting hand hygiene are crucial trends, emphasizing the need for holistic approaches to managing atopic dermatitis. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Market Driver

The high prevalence of atopic dermatitis is the key factor driving the growth of the global atopic dermatitis drugs market. The prevalence of atopic dermatitis is high worldwide. Atopic dermatitis can be caused or exacerbated by several factors, including exposure to allergens such as peanuts, pollen, and animal danger. skin irritants such as household cleaners, certain fabrics or bar soaps, stress, dry skin, and infections. In the United States alone, approximately 18 million people currently have atopic dermatitis. In the United States, an estimated 9 million to 10 million of her children under the age of 18 suffer from atopic dermatitis, about one-third of whom have moderate to severe disease. Such a large patient pool represents a huge opportunity for the growth of the market.

A large patient cohort requires multiple visits to a dermatologist and the use of numerous medications to treat atopic dermatitis, thus driving the market growth. Asia also hosts a large patient population with atopic dermatitis, with China, India, and Japan being the top three revenue contributors to the market in the region. Developing countries, such as India and China, present promising market opportunities due to their large population base. According to The World Bank Group, the population of China was 1.42 billion in 2021, while that of India was 1.41 billion in the same year. Therefore, the high prevalence of atopic dermatitis is expected to drive the growth of the market during the forecast period.

Significant Market Trends

The geopolitical uncertainties are the primary trend shaping the global atopic dermatitis drugs market. Trade policy uncertainty between nations creates an unfavorable environment for suppliers regarding investment decisions and long-term growth strategies. For instance, the pharmaceutical landscape is changing rapidly in China, with the presence of large American pharmaceutical corporations such as Pfizer, which has invested over USD 1.5 billion in the country so far. However, the trade dispute between the United States and China has adversely affected the operations of many such drug makers. This standoff has adversely affected the import of eczema medications from China into the United States.

China responded to the aggressive trade policies of the US by increasing the tariff on the imports of atopic dermatitis drugs from China. The ongoing trade war has become a major concern for manufacturers and suppliers engaged in the trade of raw materials, active pharmaceutical ingredients (API), as well as finished drugs in both countries, as they are being taxed at multiple points in the supply chain, which is adversely affecting their revenues. Such uncertainties triggered by bilateral disagreements may negatively impact the growth of the market during the forecast period.

Major Market Challenge

Loss of patents and patent expiry is a major challenge to the growth of the market. Loss or revocation of patents poses a significant threat to large companies that own their own patents. Ultimately, the loss or expiration of patents tends to flood the market with generic drugs, losing competitive advantage and margins for large companies. Generic medicines are medicines that are similar in quality, dosage form, strength, and potency to branded medicines but are available at a lower price. Due to the low-price availability of these generic drugs, increasing penetration of generic drugs will limit the market growth.

Allegations associated with the infringement of patents and other intellectual property rights by third parties affect the business of a pharmaceutical company. The expiry of the patent on branded atopic dermatitis drugs will result in the proliferation of generic drugs in the market, thus reducing the sales of branded drugs, which can negatively affect the business of prominent companies. Thus, this will hinder revenue growth prospects in the market in focus during the forecast period.

Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

 Customer Landscape

Segment Overview

The atopic dermatitis drugs market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.

• Route of Administration Outlook
  • Oral
  • Topical
  • Injectable
• Drug Class Outlook
  • Biologics
  • PDE4 inhibitors
  • Corticosteroids
  • Calcineurin inhibitors
• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • ROW
    • Australia
    • Argentina
    • Brazil

Market Analyst Overview

The market is witnessing significant advancements with the introduction of novel treatments such as biologic agents and non-steroidal topical medications. Emphasizing patient-centric care models and personalized medicine, the industry focuses on addressing symptoms like hand dermatitis, dry eye disease, and inverse psoriasis. Amidst challenges such as regulatory requirements and pricing challenges, drug development continues, spurred by opportunities in retail pharmacies and patient support programs. Corticosteroids and topical steroids remain prevalent treatments, alongside systemic treatments for severe cases.

Moreover, with an emphasis on moisturizers and emollients to alleviate symptoms, innovations in drug formulations aim to enhance patient loyalty and improve overall therapeutic outcomes. Embracing patient-centric care models, the industry focuses on addressing diverse conditions such as Sjogren’s syndrome and Frontal fibrosing alopecia. Amidst growing concerns over oil-stripping soaps and the importance of handwashing in managing skin health, there are abundant business opportunities for drug developers. Continuous drug innovations aim to alleviate symptoms and improve patient outcomes, underscoring the market's commitment to providing effective solutions for dermatological conditions.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Atopic Dermatitis Drugs Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the between 2024 and 2028
• Precise estimation of the size, market growth and forecasting, and its contribution to the market in focus to the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Market growth analysis across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of companies